Cargando…
Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer
Lenvatinib is a multi-tyrosine kinase inhibitor that inhibits angiogenesis and is currently in use for the treatment of refractory thyroid cancer. Therapy using this agent can be prolonged in patients, although serious complications may ensue among those who require surgical procedures. To the best...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947953/ https://www.ncbi.nlm.nih.gov/pubmed/33758662 http://dx.doi.org/10.3892/mco.2021.2243 |